Every letter we have printed

Your suggestion that laboratories publish the fact of a submission while keeping the result confidential is the first proposal I have read in this area that a laboratory could actually implement without breaching a client obligation. I have raised it internally.

Consider the cost. A genuinely blind programme means buying material at retail, paying full freight, waiting in the ordinary queue and absorbing the whole expense with no cooperation from the seller. That is why so little of it happens, and the reason is arithmetic rather than principle.

Protein intake is recorded in some of these trials by food diary, which has a well-characterised and large reporting error. Any analysis conditioning on that variable is conditioning on a noisy estimate and should say so.

Distribution across the day has a modest evidence base and it is a great deal weaker than the total. Presenting the two as equally established is a common error in popular summaries and it displaces attention from the number that matters.

I asked a supplier for the shipping validation behind their stated pack and received a two-page summary with a temperature profile and a duration. It took four days. The document existed the whole time and nobody had ever requested it, which is the pattern your reporting keeps finding.

Loggers have become cheap enough that a supplier could include one in every carton for the cost of the outer box. The barrier is the willingness to generate a record that might be unflattering.

Oxidation of methionine is fast, common and detectable, and the mass shift is small enough that a low-resolution instrument will miss it. It is a good example of a pathway that is easy to find if you look for it and easy to miss otherwise.

The in-source fragmentation point is worth a warning. Turn the cone voltage up far enough and a clean peptide will produce a spectrum full of fragments that look like impurities. The instrument is capable of manufacturing the finding it is being asked to test for, which is an argument for reporting the source conditions.

A practical note from a service bench. Sodium and potassium adducts are the commonest reason a first spectrum looks wrong, and they come from the glassware and the water rather than from the sample. Before anybody concludes a peptide is not what it says it is, they should check whether the offset is twenty-two.

Your article says a matching mass does not confirm a sequence, which is correct, and then rather implies that vendors are trading on the ambiguity. I run analytical services and I would put it differently: we report what we measured, in the words our clients ask for. If the Journal wants the word confirmed retired, write to the buyers, not to us.

You state that fourteen of twenty suppliers report an MS identity test. Does that count reports supplied to you on request, or only what appears on the certificate a customer receives?

The house style of giving the size of the evidence base before the finding has changed how I read everything else. It is a small habit with a large effect.

Tamper-evident packaging costs a few pence and would answer most of the questions custody is meant to answer. A sealed bag with a serial number that the laboratory records on receipt is not a chain of custody and it is a great deal better than nothing.

A practical point about labelling for submission. Write the identifier on the tube, not on a sticker, and not on the bag. Stickers come off in cold conditions and the laboratory then has a tube with no name and a bag with no contents.

Baseline composition determines a great deal of what follows, and it is the variable most often omitted from the summary. Two people losing the same mass from different starting compositions have not had the same experience.

Bariatric surgical cohorts are the other borrowed population and the mechanism differs substantially. Findings that follow from altered anatomy do not automatically follow from reduced intake, and the two literatures are frequently quoted side by side as though they were one.

Nobody has measured whether badges change behaviour. We assume they do because sellers pay for them, but sellers pay for a great many things whose effect has never been established. The absence of evidence on both sides of this argument is worth stating.

Scope is the part that most misleads. A badge earned on one molecule appears on a page listing forty, and readers reasonably take the mark as a statement about the seller rather than about the sample. Nothing on the badge disclaims the wider reading.

What a gradual reduction may do is provide a period in which habits are established while some effect remains, which is a behavioural rationale rather than a pharmacological one. Stating which kind of rationale is on offer would clarify a confused discussion.

Whatever is decided, the most useful thing anybody can do is write down the date of the last dose and what happened over the following weeks. The observational record in this area is poor mainly because nobody keeps one.

The endpoints chosen are almost entirely anthropometric, and the endpoints readers care about are frequently not. That mismatch is a funding and feasibility question rather than a scientific one, and it should be described as such.

You ask what a batch number should look like. In my experience the useful convention encodes the date and the campaign, so that a buyer can tell whether two vials bought six months apart came from the same synthesis. A serial with no structure is a label; a structured one is a small piece of traceability given away free.

I would like the retention policy printed on the certificate. A laboratory that keeps raw data for seven years and one that discards it after ninety days offer very different documents, and the difference only becomes visible at the moment you need to go back to it.

You describe reused chromatogram images as a tell. I work in a contract laboratory and I would note that some data systems export a representative overlay rather than the individual injection, so identical-looking traces can occur legitimately across a batch series. It is still worth asking about; it is not the smoking gun your article implies.

Attrition produces apparent plateaus mechanically. If people whose trajectory flattens leave the study at a different rate from those whose does not, the remaining group mean moves for reasons that have nothing to do with anybody’s response.

A statistical point. Regression to the mean will produce an apparent plateau after any period of unusually rapid change, and none of the observational accounts in circulation control for it.

As a prescribing pharmacist I would add one thing about re-titration. The commonest problem I see is not the resumption dose. It is that the patient has a pen left over at the old strength and uses it because it is in the fridge and it cost money. The clinical decision and the economic decision are not the same decision.

One more argument against reasoning past the ceiling: the exposure achieved depends on the material as well as the dose, and where peptide content is undocumented the dose is nominal. Arithmetic performed on an uncertain quantity is not made more precise by making the quantity larger.

I read this twice, which is unusual, and the second reading was the useful one. Whatever the desk is doing with structure at the moment is working.

The unit confusion in this area is a design problem rather than an education problem. A syringe graduated for one purpose, used to measure a volume of something else, will produce errors at a rate determined by the markings and not by the diligence of the person reading them.

Please keep printing the conversion in both directions. Readers can usually go from concentration to volume and stumble going back from a marking to a mass, and the second direction is the one that matters when somebody is checking what they did rather than planning it.

You recommend writing the concentration on the vial. I would add: write it on the box as well. My vial label came off in the fridge and I lost the only record of what diluent volume I had used.

Recording the site alongside the date turns a habit into data, and anybody keeping such a record for six months will learn more about their own pattern than any general advice can tell them.

A quibble on your dead-space figure. You give two to seven microlitres for insulin-type needles, which is right for fixed-needle syringes, but the detachable pen needle plus syringe hub combinations sold in this market are considerably worse and you should say so.

Aggregation is not degradation in the chemical sense and it is reported as though it were. The molecule is intact and its physical state has changed, which is a different problem with different consequences.

Freeze-thaw deserves its own warning. Repeated cycling concentrates solutes at the ice interface and is far harder on a reconstituted solution than a steady temperature a few degrees higher. The domestic freezer door is the worst place in the house for this material and the place most people put it.

I have shipped temperature-sensitive material commercially for eleven years and your coolant arithmetic is right but generous. You assume the pack starts fully frozen. In practice packs are pulled from a freezer that is opened forty times a day, and a pack that starts at minus four with a soft core has lost a fair share of its budget before the box is closed.

Deamidation at asparagine is the dominant route for several of these sequences and it is strongly pH dependent, which makes the reconstitution diluent a stability decision rather than a convenience one. Bacteriostatic water is not neutral in this respect and very few people treat it as a variable.

Thank you for declining to tell readers what to do. The restraint is unusual and it is the reason I trust what you do print.

Documentation of the cold chain between the fill site and dispatch is the leg that is genuinely under the supplier’s control, and it is the one nobody asks about. Everything before the courier is theirs to describe.